Recombinant Coagulation Factors Market: Increasing demand for diagnosis rates for prevention of bleeding are likely to fuel the market growth

2021-02-10
The advancement in technology that has endorsed manufacturing of recombinant proteins on a large scale industrial production for development of hemophilia and thrombosis treatments. Recombinant coagulation factors, as opposed to plasma-derived counterparts, consume a very low risk for transfer of infectious diseases and their use would eliminate the risk of infection from viruses such as the human immunodeficiency virus and hepatitis C. The advancement of recombinant coagulation factors has been a major importance in hemophilia care promising nearly complete safety of individuals from the risk of transmitted infections. Request Brochure for Report – Global Recombinant Coagulation Factors Market Witness Most Promising Rise in Demand: Rising number of hemophilia patients across the world, growing prophylactic treatment, and increasing demand for diagnosis rates for prevention of bleeding are likely to fuel the growth of recombinant coagulation factors market. In addition, increasing research and development activities on recombinant factor VIII is projected to boost the growth of the recombinant coagulation factors market. However, high cost treatment of hemophilia care and low cost treatment from plasma coagulation factor available alternatives to recombinant coagulation factors are obstructing the growth of recombinant coagulation factors market. While the R&D pipeline of recombinant coagulation factors is growing, other methods are strongly developing in early clinical development which may become the real threat to the recombinant coagulation factors market. The recombinant coagulation factors market can be segmented based on type, hemophilia type, end-user, and region. In terms of type, the market can be categorized into recombinant factor VIII, recombinant factor IXa, recombinant factor VIIa, and Von Willebrand factor. Recombinant factor VIIa or (rFVIIa) is available for treatment of people suffering from hemophilia with inhibitors who experience bleeding or require surgery. Recombinant or human plasma-derived factor IX products are used in the treatment and prevention of bleeding in patients with hemophilia B. Wide acceptance of recombinant coagulation factors throughout the developed world has considerably increased the supply of coagulation factor that concentrates and helped development of aggressive therapeutic interferences such as prophylaxis. Request for Analysis of COVID19 Impact on Recombinant Coagulation Factors Market – The global recombinant coagulation factors market can be segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the market, followed by Europe. Increasing demand for treatment and rising patient awareness about different treatment options drive the market in North America. The recombinant coagulation factors market is growing owing to increasing population and rising demand for rapid diagnosis and better treatment for hemophilia globally. In addition, the global recombinant coagulation factors market is expected to grow at a high rate in the next few years. Increasing medical tourism in developing countries, rising investments by market players in Asia Pacific, especially in India and China, and growing awareness about hemophilia treatment are likely to drive the market in Asia Pacific during the forecast period. Key Players of Recombinant Coagulation Factors Market Report: Key players operating in the global recombinant coagulation factors market are Bayer, Wyeth, Baxter International, Inc., P?zer, Inc., Novo Nordisk, Octapharma AG, Emergent BioSolutions Inc., CSL Behring, and Biogen. Increasing competition among key players to develop new therapy for hemophilia is projected to drive the recombinant coagulation factors market. Buy Recombinant Coagulation Factors Market Report – About Us Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. Contact Transparency Market Research, 90 State Street, Suite 700, Albany, NY 12207 Tel: +1-518-618-1030 USA - Canada Toll Free: 866-552-3453 Website:
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。